Browse by Poster Presenter

iwCLL X / Twitter

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Browse by Poster Presenter

Type here to filter the list

I
Iatrou, Anastasia

Institute of Applied Biosciences, Centre for Research and Technology Hellas
1009 - IMMUNOGENETICS AND ANTIGEN REACTIVITY PROFILING CONTRIBUTE TO UNRAVELLING THE ONTOGENY OF CLL STEREOTYPED SUBSET #4
Anastasia Iatrou
Favorite
Illmer, Thomas

Group Practice for Hematology and Oncology
1212 - Targeted agents in chronic lymphocytic leukemia (CLL): Data on outcomes and subsequent therapies of patients observed within the German CLL Study Group (GCLLSG) registry
Thomas Illmer
Favorite
Inchiappa, Luca

Institut Paoli Calmettes
1211 - Venetoclax as an Alternative and Effective Treatment in Central Nervous System Involvement of Chronic Lymphocytic Leukemia: Monocentric Experience
Luca Inchiappa
Favorite
4005 - STop and Restart Acalabrutinib In fRail Patients With Previously Untreated Chronic Lymphocytic Leukemia (STAIR): a randomized phase 2 study from the FILO-CLL group
Luca Inchiappa
Favorite
Injac, Sarah

Nurix Therapeutics, Inc.
3008 - An ongoing first-in-human phase 1 trial of NX-5948, an oral Bruton’s tyrosine kinase (BTK) degrader, in patients with relapsed/refractory B cell malignancies, including chronic lymphocytic leukemia (CLL)
Sarah Injac
Favorite
Innao, Vanessa

UOC di Ematologia, Azienda Ospedaliera di rilievo nazionale di alta specializzazione, ARNAS – Garibaldi di Catania
1222 - KINETICS OF LYMPHOCYTOSIS DURING BTK COVALENT INHIBITORS IN TREATMENT NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS. AN ITALIAN MULTICENTER EXPERIENCE OF REAL LIFE.
Vanessa Innao
Favorite
Innocenti, Idanna

Section of Hematology, Department of Radiological and Hematological Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS
1201 - Impact of COVID-19 in patients with Chronic Lymphocytic Leukemia treated with venetoclax: a possible role of the association to anti-CD20 antibody? A multicentre SEIFEM study.
Idanna Innocenti
Favorite
1203 - Chronic obstructive pulmonary disease and previous infections have impact on infectious complications in patients with Chronic Lymphocytic Leukemia treated with venetoclax: a multicentre SEIFEM study.
Idanna Innocenti
Favorite
1219 - The evolution of treatments and outcome of patients with chronic lymphocytic leukemia treated at Fondazione Policlinico Universitario Agostino Gemelli IRCCS: a monocentric experience of the Last 30 Years.
Idanna Innocenti
Favorite
1222 - KINETICS OF LYMPHOCYTOSIS DURING BTK COVALENT INHIBITORS IN TREATMENT NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS. AN ITALIAN MULTICENTER EXPERIENCE OF REAL LIFE.
Idanna Innocenti
Favorite
1224 - Incidence of arrhythmia in chronic lymphocytic leukemia (CLL) patients treated with ibrutinib: a real-world retrospective analysis from two Italian centers.
Idanna Innocenti
Favorite
Irigoín, Victoria

COSEM
1037 - Activation of S100-A9/EMMPRIN axis triggers survival/proliferation pathways in leukemic cells. A novel target for chronic lymphocytic leukemia
Victoria Irigoín
Favorite
1144 - Patients with unmutated IgHV_1-69; 1-02; 3-30; 4-39 and high expression of AID enzyme need earlier treatment.
Victoria Irigoín
Favorite
Isenalumhe, Leidy

H Lee Moffitt Cancer Center & Research Institute
1119 - Treatment Strategies and Outcomes for Double Refractory chronic lymphocytic leukemia; A single center experience
Leidy Isenalumhe
Favorite
Isufi, Iris

Yale University School of Medicine
2024 - Phase 1/2 Study of Zilovertamab and Ibrutinib: Durable responses suggest a novel mechanism for synthetic lethality in TP53 aberrant disease.
Iris Isufi
Favorite
Itchaki, Gilad

Meir Medical Center
1113 - Pericardial effusion in patients with chronic lymphocytic leukemia treated with Bruton's tyrosine kinase inhibitors
Gilad Itchaki
Favorite
Ivek, Ida

UHC Zagreb
1225 - Real-world evidence on venetoclax in chronic lymphocytic leukemia: The KROHEM (Croatian cooperative group for hematological diseases) experience
Ida Ivek
Favorite
Ivic, Marija

University Hospital Dubrava
1019 - Chemokine receptor and adhesion molecule profile on B-cell chronic lymphocytic leukemia (B-CLL) lymphocytes in different lymphoid compartments and changes during BTK inhibitor therapy
Marija Ivic
Favorite
1124 - Efficacy and toxicity of ibrutinib in CLL - Croatian experience. A non-interventional, real world study of KroHem
Marija Ivic
Favorite
1225 - Real-world evidence on venetoclax in chronic lymphocytic leukemia: The KROHEM (Croatian cooperative group for hematological diseases) experience
Marija Ivic
Favorite
Izutsu, Koji

Department of Hematology, National Cancer Center Hospital
1126 - Significance of sIL-2R and LD in predicting time to first treatment in Japanese CLL patients with early asymptomatic disease.
Koji Izutsu
Favorite